

Hall of the House of Representatives
95th General Assembly - Regular Session, 2025
Amendment Form

Subtitle of House Bill 1332

TO REQUIRE THE ARKANSAS MEDICAID PROGRAM TO COVER GLUCAGON-LIKE
PEPTIDE-1 RECEPTOR AGONISTS, ALSO KNOWN AS GLP-1 AGONISTS, WHEN
PRESCRIBED FOR WEIGHT LOSS.

Amendment No. 2 to House Bill 1332

Amend House Bill 1332 as engrossed H3/31/25 (version: 3/31/25 11:41:50 AM):

Add Senator J. Scott

AND

Page 1, delete lines 10 through 12, and substitute the following:
"EVALUATE CLAIMS FOR DIAGNOSES FREQUENCY OF OBESITY-RELATED CONDITIONS AND
PRESENT THE COSTS; TO ALLOW HEALTH BENEFIT PLANS TO OFFER OPTIONAL COVERAGE
OF UNITED STATES FOOD AND DRUG ADMINISTRATION-APPROVED ANTI-OBESITY
MEDICATION; AND FOR OTHER PURPOSES."

AND

Delete the subtitle in its entirety and substitute:

"TO REQUIRE THE ARKANSAS MEDICAID PROGRAM
TO EVALUATE CLAIMS FOR DIAGNOSES
FREQUENCY OF OBESITY-RELATED CONDITIONS
AND PRESENT THE COSTS."

AND



Delete everything after the enacting clause and substitute the following:

"SECTION 1. Arkansas Code Title 20, Chapter 77, Subchapter 154, is amended to add an additional section to read as follows:

20-77-154. Obesity-related conditions.

(a) The Department of Human Services shall evaluate claims level data for diagnoses frequency of obesity-related conditions including without limitation Type 2 diabetes, pre-diabetes, cardiovascular disease, heart failure, hypertension, chronic kidney disease, metabolic dysfunction-associated steatohepatitis, liver disease, obstructive sleep apnea, osteoarthritis, and other obesity-related conditions within the Medicaid population.

(b) The department shall document the cost of these obesity-related conditions and show trend data, year over year of the rising trends of both the diagnoses frequency and cost to the state to present at least sixty (60) days before a regular or fiscal legislative session to the:

- (1) House Committee on Public Health, Welfare, and Labor; and
- (2) Senate Committee on Public Health, Welfare, and Labor.

SECTION 2. Arkansas Code Title 23, Chapter 79, Subchapter 1, is amended to add an additional section to read as follows:

23-79-169. Optional coverage for United States Food and Drug Administration-approved anti-obesity medications – Definition.

(a) As used in this section, "United States Food and Drug Administration-approved anti-obesity medication" means a medication approved by the United States Food and Drug Administration with an indication for weight management in patients with chronic obesity.

(b)(1) A health benefit plan that is offered, issued, or renewed in this state shall allow the policyholder the option to purchase coverage for United States Food and Drug Administration-approved anti-obesity medications.

(2) The health benefit plan may adopt standards and criteria that a covered person shall meet to be eligible for United States Food and Drug Administration-approved anti-obesity medications consistent with standards established by rule of the State Insurance Department.

(c) Subsection (b) of this section does not apply to a government

self-insured plan."

The Amendment was read _____
By: Representative Pilkington
JMB/JMB - 04-08-2025 09:25:16
JMB658

Chief Clerk